Genscript Biotech Corp.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: HKG:1548
Genscript Biotech Corp is a China-based provider of life science research services and products. The firm is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. The company's business segments include Life-science services and products, Biologics development services, Industrial synthetic biology products, and the Operation unit. The company generates the majority of its revenue from the life-science services and products unit, which provides comprehensive research services and products, which are widely used and are fundamental to life-science research and application. Geographically, the company generates the majority of its revenue from the United States of America, followed by Mainland China.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 107 out of 843
Universe
Global Universe 5084 out of 14631
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Syngene International Ltd. |
15.6
Low
|
24 out of 843 |
Suven Pharmaceuticals Ltd. |
16.5
Low
|
36 out of 843 |
Asymchem Laboratories (Tianjin) Co., Ltd. |
19.1
Low
|
66 out of 843 |
BGI Genomics Co., Ltd. |
19.4
Low
|
70 out of 843 |
Genscript Biotech Corp. |
21.9
Medium
|
107 out of 843 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Genscript Biotech Corp.'s Exposure is Low
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Genscript Biotech Corp.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Top Material ESG Issues for Genscript Biotech Corp.
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.

What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted Genscript Biotech Corp.'s ESG Risk Rating in the last three years
Highest Controversy Level

Contributing Events

Highest Controversy Events Locations
